Loading clinical trials...

Psoriatic Arthritis Pathobiology and Its Relationship With Clinical Disease Activity | Clinical Trials | Clareo Health

COMPLETED

Psoriatic Arthritis Pathobiology and Its Relationship With Clinical Disease Activity

NCT06676176•Barts & The London NHS Trust

Summary

The study aims to examine the relationship between synovial histopathology and change in clinical disease activity over time in a population of patients with psoriatic arthritis who have failed to respond to first-line treatment. It is a prospective, open-labelled study

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Men and women between 18 and 75 years of age inclusive;
•2. Patients with Psoriatic Arthritis as defined by the CASPAR criteria;
•3. Patients who have persistent active disease (defined as having 3 or more swollen and 3 or more tender joints) despite an adequate trial of 2 or more standard non-biologic disease-modifying drugs, administered either individually or in combination;
•4. Subjects who are naïve to biologic therapy or who have experienced but failed one previous class of biologic agent;
•5. The patient must be able to comply with the study visit schedule, treatment plans, lab tests and other study procedures;
•6. The patient must be capable of giving informed consent.

Exclusion Criteria

•1. Women who are pregnant or breastfeeding;
•2. Men and women of childbearing potential who decline to employ adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study;
•3. As per care within a standard NHS setting, active infections of a serious nature such as HIV, HBV, pneumonia, or pyelonephritis are to be excluded. A history of previous serious infection is to be assessed individually for risk of re-activation, and a decision to treat (and with which agent) would be made according to the treating physician's discretion, as would normally occur within standard care. Less serious infections (such as upper respiratory tract infection \[colds\] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator;
•4. Active TB, or evidence of latent TB without adequate therapy for TB, initiated prior to first dose of biologic. Also excluded are patients with evidence of an old or latent TB infection without documented adequate therapy. Patients with previous or current close contact with an individual with active TB, or history of active TB, and patients who have completed treatment for active TB should have had a thorough evaluation for TB prior to study enrolment as recommended by a local infectious disease specialist or published local guidelines of TB control agencies;
•5. History of septic arthritis within a native joint within the last 12 months;
•6. Presence of a transplanted organ (with the exception of a corneal transplant occurring more than 3 months prior to screening);
•7. Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated, with no evidence of recurrence);
•8. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly;
•9. Known recent substance abuse (drug or alcohol);
•10. History of or current primary inflammatory joint disease or primary rheumatological autoimmune disease other than PsA;
+2 more criteria

Locations (1)

Barts Health NHS Trust

London, United Kingdom

Key Dates

Start Date

June 1, 2015

Primary Completion Date

June 24, 2020

Completion Date

June 24, 2020

Last Updated

November 6, 2024

Enrollment

ACTUAL participants

Conditions

Arthritis, Psoriatic

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

NCT06522035

Arthritis, Psoriatic

View study

NOT_YET_RECRUITING

Pain in Inflammatory Joint Diseases

NCT06718569

ArthritisArthritis, Juvenile Idiopathic+4 more

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Psoriatic Arthritis Pathobiology and Its Relationship With Clinical Disease Activity

Inclusion Criteria

Exclusion Criteria

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Pain in Inflammatory Joint Diseases

Biologic Treatment Registry Across Canada

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Effectiveness of Digital Rehabilitation (SIMPLI.REHAB) in Hand Arthritis